Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2025
Reporting Period: As of March 11, 2025
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. This filing addresses an update to its At The Market (ATM) Offering Agreement with Ladenburg Thalmann & Co. Inc.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The following capital structure and liquidity-related figures are disclosed:
- Shares Outstanding: 6,783,543 shares of Common Stock as of March 11, 2025.
- ATM Offering Capacity Remaining: $1,376,530.39 in aggregate gross sales price available for offer and sale.
- Total Shelf Registration Capacity: $100,000,000 (under the Base Prospectus).
- Original ATM Authorization: Up to $3.0 million (filed September 18, 2024).
Material Changes
ATM Prospectus Supplement: On March 11, 2025, the Company filed a prospectus supplement (the "2025 Supplement") to its existing ATM Prospectus. This action updates the offering to include the sale of "Additional Shares" with an aggregate gross sales price of up to $1,376,530.39, which remained available under the original registration statement.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the Company's intent to continue utilizing the ATM Agreement to sell shares from time to time through Ladenburg Thalmann & Co. Inc. as sales agent and/or principal.
Risks and Contingencies: The filing notes that sales are subject to eligibility and transaction requirements for Form S-3, including General Instruction I.B.6. The amount of shares sold is limited by the lesser of the registered amount, authorized unissued shares, or amounts that would violate Form S-3 eligibility.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the current market price of INBS common stock to assess the dilution impact of the remaining $1,376,530.39 ATM capacity.
- Confirm the total number of authorized but unissued shares to ensure the ATM offering does not exceed capital stock limits.
- Review the Company's most recent 10-K or 10-Q for actual revenue, cash flow, and debt positions, as this 8-K does not contain operational financial data.
- Monitor future 8-K filings for actual sales executed under the ATM Agreement to track cash raised and share count increases.